You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype

    SBC: Haplomics            Topic: NIMHD

    Evaluation of the Antigenicity of Black-Restricted Haplotypes of Factor VIII ABSTRACT About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Such patients, who are termed inhibitor patients, are typically treated with so called bypassing agents such as recombinant (r) FVIIa and FEIBA. Bypassing agents are mor ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: NIGMS

    DESCRIPTION: Glycans have several distinct properties that make them excellent targets for disease biomarkers. Firstly, the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in thecontrol of normal metabolic processes. Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for t ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Reduce the Risk: An Affect Management Program for HIV Prevention

    SBC: VIRTUALLY BETTER INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The proposed project, titled Reduce the Risk: An Affect Management Program for HIV Prevention, will examine the use of immersive virtual reality technology as an intervention tool for HIV Prevention with adolescents. Adolescents are at risk for contracting HIV. Affect dysregulation is common among adolescents. Research has demonstrated connections between poor ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. System for multidimensional analysis of growth and migration of neurons and neuro

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induced progressive multifocal leukoencephalopathy (PML). PMLis a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid-1980s ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Drug Resistant HIV: Novel Target Validation and Small Molecule Lead Discovery

    SBC: GEOVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): HIV/AIDS remains a major health problem and there is a need for effective and durable HIV vaccines. Establishing potent and durable antibodies (Ab) that have neutralizing and non-neutralizing mechanisms can contribute to the prevention of mucosal HIV infection. Findings from the recent RV144 trial have highlighted a significant role for protective non-neutraliz ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government